Canadian Cancer Trials Group Bulletins

General


More Canadian Cancer Trials Group-Related ASCO Abstracts

In addition to the 27 abstracts presented at the American Society of Clinical Oncology Annual Meeting and identified in the previous Bulletin, an additional 10 abstracts related to trials that included Canadian Cancer Trials Group participation were presented. They include:

Canadian Cancer Trials Group CRC.2 (NCCTG 0147) - A Randomized Phase III Trial of Oxaliplatin (OXAL) Plus 5-Fluouracil (5-FU)/Leucovorin (CF) with or without Cetuximab (C225) after Curative Resection for Patients with Stage III Colon Cancer

J. Huang, D. J. Sargent, M. R. Mahoney, A. F. Shields, E. Chan, R. M. Goldberg, S. Gill, M. S. Kahlenberg, J. T. Quesenberry, T. C. Smyrk, A. Grothey, F. Sinicrope, S. G. Nair, S. R. Alberts. Pilot experience with adjuvant FOLFIRI with or without cetuximab in patients with resected stage III colon cancer: NCCTG Intergroup N0147. J Clin Oncol 29: 2011 (suppl; abstr 3522)

S. R. Alberts, S. N. Thibodeau, D. J. Sargent, M. R. Mahoney, F. Sinicrope, A. F. Shields, E. Chan, R. M. Goldberg, S. Gill, M. S. Kahlenberg, J. T. Quesenberry, T. C. Smyrk, A. Grothey, S. G. Nair. Influence of KRAS and BRAF mutational status and rash on disease-free survival (DFS) in patients with resected stage III colon cancer receiving cetuximab (Cmab): Results from NCCTG N0147. J Clin Oncol 29: 2011 (suppl; abstr 3607)

J. A. Sloan, M. R. Mahoney, D. J. Sargent, J. M. Hubbard, H. Liu, E. M. Basch, A. F. Shields, E. Chan, R. M. Goldberg, S. Gill, M. S. Kahlenberg, S. R. Alberts. Was it worth it (WIWI)? Patient satisfaction with clinical trial participation: Results from North Central Cancer Treatment Group (NCCTG) phase III trial N0147. J Clin Oncol 29: 2011 (suppl; abstr 6122)

M. R. Mahoney, J. A. Sloan, J. M. Hubbard, H. Liu, A. F. Shields, E. Chan, R. M. Goldberg, S. Gill, M. S. Kahlenberg, S. G. Nair, D. J. Sargent, S. R. Alberts . Quality of life (QOL) for patients treated with FOLFOX with or without cetuximab (Cmab) following complete resection of colorectal cancer (CRC): Results from North Central Cancer Treatment Group (NCCTG) phase III trial N0147. J Clin Oncol 29: 2011 (suppl; abstr 3541)

Canadian Cancer Trials Group CO.13 (NCCTG 9741) - A Randomized Phase III Trial of Combinations of Oxaliplatin (OXAL), 5-fluorouracil (5-FU), and Irinotecan (CPT-11) as Initial Treatment of Patients with Advanced Adenocarcinoma of the Colon and Rectum

A. Grothey, J. M. Heun, M. Branda, R. M. Goldberg, D. J. Sargent. New lesions versus growth of existing disease: Does it impact prognosis? J Clin Oncol 29: 2011 (suppl; abstr 2579).

Canadian Cancer Trials Group CO.14 (CALGB 9581) - Phase III Randomized Study of Adjuvant Immunotherapy with Monoclonal Antibody 17-1A versus No Adjuvant Therapy Following Resection for Stage II (Modified Astler-Coller B2) Adenocarcinoma of the Colon

A. P. Venook, D. Niedzwiecki, M. Lopatin, M. Lee, P. N. Friedman, W. Frankel, K. Clark-Langone, C. Yoshizawa, C. Millward, S. Shak, R. M. Goldberg, N. N. Mahmoud, R. L. Schilsky, M. M. Bertagnolli, Cancer and Leukemia Group B. Validation of a 12-gene colon cancer recurrence score (RS) in patients (pts) with stage II colon cancer (CC) from CALGB 9581. J Clin Oncol 29: 2011 (suppl; abstr 3518).

Canadian Cancer Trials Group CO.15 (CALGB 89803) - A Phase III Intergroup Trial of Irinotecan (CPT-11) (NSC #616348) Plus Fluorouracil/Leucovorin (5-FU/LV) Versus Fluorouracil / Leucovorin Alone After Curative Resection for Patients with Stage III Colon Cancer

K. Van Loon, D. Wigler, D. Niedzwiecki, D. Hollis, A. P. Venook, C. D. Blanke, L. Saltz, R. M. Goldberg, C. S. Fuchs, J. A. Meyerhardt. A comparison of dietary and lifestyle habits among stage III and metastatic colorectal cancer patients. J Clin Oncol 29: 2011 (suppl; abstr e14026).

Canadian Cancer Trials Group GAC.1 (CALGB 80101) - Phase III Randomized Study of Adjuvant Chemoradiation After Resection in Patients with Gastric or Gastroesophageal Adenocarcinoma

C. S. Fuchs, J. E. Tepper, D. Niedzwiecki, D. Hollis, H. J. Mamon, R. ett, P. C. Enzinger, R. M. Goldberg, A. P. Venook, R. J. Mayer. Postoperative adjuvant chemoradiation for gastric or gastroesophageal junction (GEJ) adenocarcinoma using epirubicin, cisplatin, and infusional (CI) 5-FU (ECF) before and after CI 5-FU and radiotherapy (CRT) compared with bolus 5-FU/LV before and after CRT: Intergroup trial CALGB 80101. J Clin Oncol 29: 2011 (suppl; abstr 4003).

Canadian Cancer Trials Group PA.2 (ESPAC-3(v2) - Phase III Adjuvant Trial in Pancreatic Cancer Comparing (1) 5FU and D-L Folinic Acid vs (2) Gemcitabine vs (3) No Adjuvant Treatment

J.P. Neoptolemos, M. J. Moore, T. F. Cox, J. W. Valle, D. H. Palmer, A. Mcdonald, R. Carter, N. C. Tebbutt, C. Dervenis, D. Smith, B. Glimelius, F. Y. Coxon, F. Lacaine, M. R. Middleton, P. Ghaneh, C. Bassi, C. Halloran, A. Olah, C. L. Rawcliffe, European Study Group for Pancreatic Cancer, M. W. Büchler . Ampullary cancer ESPAC-3 (v2) trial: A multicenter, international, open-label, randomized controlled phase III trial of adjuvant chemotherapy versus observation in patients with adenocarcinoma of the ampulla of vater. J Clin Oncol 29: 2011 (suppl; abstr LBA4006).

Canadian Cancer Trials Group PA.5 (LAP.07) - A Factorial Design (opt) Randomized Phase III Trial of Gemcitabine +/- Erlotinib and Additional Subsequent Chemotherapy vs Chemo-Radiation Therapy For Patients With Locally Advanced Pancreatic Cancer

P. Hammel, F. Huguet, J. Van Laethem, D. Goldstein, B. Glimelius, M. J. Moore, B. Chibaudel, F. Bonnetain, C. Louvet, glimelius. Randomized multicenter phase III study in patients with locally advanced adenocarcinoma of the pancreas: Gemcitabine with or without chemoradiotherapy and with or without erlotinib-LAP 07 study. J Clin Oncol 29: 2011 (suppl; abstr e14619).

Congratulations to all!